Release date: 2018-05-29
Science and Technology Daily, Beijing, May 28 (Reporter Zhang Mengran) CAR-T cell therapy is considered a revolutionary cancer therapy, according to two independent mouse studies published online by the British journal Nature Medicine on the 28th, Europe and the United States. Scientists have shown that after the addition of interleukin-1 (IL-1) inhibitors, CAR-T cell immunotherapy will be safer and more widely used.
The promising CAR-T therapy marks a new era in cancer treatment. The essence is an immunotherapy of genetically modified autologous T cells and a "customized treatment" using the patient's own T cells. Recently, two types of CAR-T cell therapies have been approved for the treatment of extremely refractory forms of cancer, and many more have shown therapeutic effects in clinical trials. However, these treatments have serious potential side effects - neurotoxicity and cytokine release syndrome (CRS) that can cause death, which are still major challenges to overcome.
Due to the lack of animal models, people have been slow to know exactly how CAR-T cells cause these side effects. To solve this problem, Attilio Bodanze, a scientist at the San Rafael Institute of Science in Italy, and his colleagues transformed mice to have a human-like immune system. They found that both CRS and neurotoxicity are triggered by the inflammatory molecule IL-1, and the addition of anakinra, which inhibits IL-1, to the treatment regimen blocks the molecule.
In the US Memorial Sloan-Kettering Institute, scientist Michael Sadeland and colleagues used another mouse model and found that CRS is caused by IL-1 and other inflammatory molecules, and drugs can be used. Inhibitors are treated. In addition, they inserted the IL-1 inhibitor gene directly into CAR-T cells to prevent, rather than treat, CRS.
In the accompanying news and opinion article, scientists at the Cell and Gene Therapy Center at Baylor College of Medicine in the United States believe that complementary findings from two independent laboratories indicate that targeting IL-1 or improving CAR- via anakinra T cell design can eliminate the risk of CRS and neurotoxicity. However, it is worth noting that these findings have yet to be validated in clinical trials because the mouse model is only similar to human disease.
Source: Technology Daily
Greenhouse Plastic Plastic Clamps
Greenhouse Plastic Plastic Clamps,Greenhouse Structure Connecting Clamps,Agricultural Greenhouses Clamps,Plastic Clamps
JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.greenhousehydroponic.com